Ranbaxy Laboratories said on Monday it had been chosen by the Geneva-based Medicines for Malaria Venture to replace Roche Pharma as its partner to develop an anti-malaria drug.
The partners expect the new synthetic peroxide drug, for which New Delhi-based Ranbaxy will have worldwide registration and sale rights, to reduce the treatment period to three days and cost much less than current artemisinin derivatives.
